| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06953583 | A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia | PHASE3 | RECRUITING | 255 | — | — | Jun 9, 2025 | Nov 22, 2029 | Jun 3, 2026 | 34 | United States, Australia +14 |
| NCT02255435 | A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia | PHASE2 | COMPLETED | 172 | — | — | Jan 31, 2015 | Dec 19, 2025 | Jan 23, 2026 | 11 | United States, Australia +3 |
| NCT06054893 | A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old | PHASE1 | ACTIVE NOT_RECRUITING | 33 | — | — | Jul 1, 2024 | Nov 22, 2030 | May 11, 2026 | 1 | United States |
The mFARS is a validated and sensitive rating scale that was developed to quantitatively assess the severity of the neurologic features of FA in adults and adolescents. Scores on the mFARS range from 0 to 93, with lower scores indicating better neurological function. The subscales of the mFARS assessment and maximum score for each subscale are: bulbar function (Subscale A; 2 assessments of speech and cough; maximum score = 5), upper limb coordination (Subscale B; 5 assessments of coordination of movement and function in arms and hands with each limb scored individually; maximum score = 36), lower limb coordination (Subscale C; 2 assessments of coordination of movement and function of lower limbs with each limb scored individually; maximum score = 16), and upright stability (USS, Subscale E; 9 assessments of sitting posture, stance, tandem walk, and gait assessments; maximum score = 36).
The mFARS is a validated and sensitive rating scale that was developed to quantitatively assess the severity of the neurologic features of FA in adults and adolescents. Scores on the mFARS range from 0 to 93, with lower scores indicating better neurological function. The subscales of the mFARS assessment and maximum score for each subscale are: bulbar function (Subscale A; 2 assessments of speech and cough; maximum score = 5), upper limb coordination (Subscale B; 5 assessments of coordination of movement and function in arms and hands with each limb scored individually; maximum score = 36), lower limb coordination (Subscale C; 2 assessments of coordination of movement and function of lower limbs with each limb scored individually; maximum score = 16), and upright stability (USS, Subscale E; 9 assessments of sitting posture, stance, tandem walk, and gait assessments; maximum score = 36).
The C-SSRS is a low-burden measure of the spectrum of suicidal ideation and behavior that was developed to assess severity and track suicidal events through any treatment of individuals ≥ 6 years of age. The C-SSRS is a clinical interview providing a summary of both ideation and behavior that can be administered by the clinician during any evaluation or risk assessment to identify the level and type of suicidality present. The assessment includes "yes" or "no" responses for 5 questions each, related to suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan) and suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, suicide). Numeric ratings are provided for severity of ideation, from 1 to 5, with 5 being the most severe.
Assessment of Tanner stages (a scale of physical development) will be performed by a medical doctor experienced with this assessment. Tanner score ranges from Stage 1 (childhood) to Stage 5 (full physical maturity). Information regarding Tanner staging will be collected at baseline for all participants and will be stopped once the participant reaches Tanner Stage 5 in all gender-appropriate scales.
Assessment of Tanner stages (a scale of physical development) will be performed by a medical doctor experienced with this assessment. Tanner score ranges from Stage 1 (childhood) to Stage 5 (full physical maturity). Information regarding Tanner staging will be collected at baseline for all participants and will be stopped once the participant reaches Tanner Stage 5 in all gender-appropriate scales.
Peak work attained during maximal exercise testing. Cycle ergometry using a recumbent stationary bicycle was used, and workload was increased incrementally. Peak work is defined as the workload at which patients reach maximal volition (defined as an inability to continue to exercise due to exhaustion).
The mFARS includes 4 of the 5 sections of the Friedreich's Ataxia Rating Scale (FARS): bulbar (score 0 to 11), upper limb coordination (score 0 to 36), lower limb coordination (score 0 to 16), and upright stability (score 0 to 36). The minimum score is 0 and the maximum score is 99. A lower score indicates better neurological function.
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal (investigational) product, whether or not related to medicinal (investigational) product. SAE is any untoward medical occurrence that at any dose results in death, in the view of investigator, places the participant at immediate risk of death (life-threatening event), requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in congenital anomaly/birth defect or is medically important event.
Vital signs, including blood pressure (BP), heart rate (HR), and oral body temperature, will be assessed.
| Arm | Type | Description |
|---|---|---|
| Part 1: Omaveloxolone | EXPERIMENTAL | Participants will receive a single oral dose of omaveloxolone once a day (QD) for up to 52 weeks in Part 1 of the study. |
| Part 1: Placebo | PLACEBO_COMPARATOR | Participants will receive placebo, orally, QD for up to 52 weeks in Part 1 of the study. |
| Part 2A Continued Efficacy Evaluation: Omaveloxolone | EXPERIMENTAL | Participants will receive a single oral dose of omaveloxolone, QD for up to 104 weeks in Part 2A of the study. |
| Part 2B Safety: Omaveloxolone | EXPERIMENTAL | Participants will receive a single oral dose of open-label omaveloxolone, QD for up to 104 weeks in Part 2B of the study. |
| Part 1 Omaveloxolone Capsules 2.5 and 5 mg | EXPERIMENTAL | omaveloxolone (RTA 408) Capsules, 2.5 mg administered orally one daily for 2 weeks, then 5 mg taken orally once daily for 10 weeks |
| Part 1 Omaveloxolone Capsules 10 mg | EXPERIMENTAL | omaveloxolone (RTA 408) Capsules, 10 mg administered orally once daily for 12 weeks |
| Part 1 Omaveloxolone Capsules 20 mg | EXPERIMENTAL | Omaveloxolone (RTA 408) Capsules, 20 mg administered orally once daily for 12 weeks |
| Part 1 Omaveloxolone Capsules 40 mg | EXPERIMENTAL | Omaveloxolone (RTA 408) Capsules, 40 mg administered orally once daily for 12 weeks |
| Part 1 Omaveloxolone Capsules 80 mg | EXPERIMENTAL | Omaveloxolone (RTA 408) Capsules, 80 mg administered orally once daily for 12 weeks |
| Part 1 Omaveloxolone Capsules 160 mg | EXPERIMENTAL | Omaveloxolone (RTA 408) Capsules, 160 mg administered orally once daily for 12 weeks |
| Part 1 Omaveloxolone Capsules 300 mg | EXPERIMENTAL | Omaveloxolone (RTA 408) Capsules, 300 mg administered orally once daily for 12 weeks |
| Part 1 Placebo Capsules | PLACEBO_COMPARATOR | Placebo capsules administered orally once daily for 12 weeks |
| Part 2 Placebo Capsules | PLACEBO_COMPARATOR | Placebo capsules administered orally once daily for 48 weeks |
| Part 2 Omaveloxolone Capsules 150 mg | EXPERIMENTAL | Omaveloxolone (RTA 408) Capsules, 150 mg administered orally once daily for 48 weeks |
| Part 1 and 2: Cohort A1 | EXPERIMENTAL | Cohort A1 will contain participants 12 to \<16 years of age. Participants will receive a single oral dose of omaveloxolone, 150 milligrams (mg), capsule, on Day 1 of the treatment period of part 1, followed by the same dose in part 2 up to week 240 or commercial availability whichever comes first. The dose in part 2 may be adjusted as per additional safety and Bayesian population pharmacokinetics (popPK) analyses. |
| Part 1 and 2: Cohort A2 | EXPERIMENTAL | Cohort A2 will contain participants 12 to \<16 years of age. Participants will receive a single oral dose of omaveloxolone, capsule, at a dosage level determined by a Bayesian popPK analysis using the data from Cohort A1 to select the dose in part 1, followed by the same dose in part 2 up to week 240 or commercial availability whichever comes first. The dose in part 2 may be adjusted as per additional safety and Bayesian popPK analyses. |
| Part 1 and 2: Cohort B1 | EXPERIMENTAL | Cohort B1 will contain participants 7 to \<12 years of age and will initiate in parallel with Cohort A2. Participants will receive a single oral dose of omaveloxolone, capsule, at a dosage level determined by a Bayesian popPK analysis using the data from Cohort A1 to select the dose in part 1, followed by the same dose in part 2 up to week 240 or commercial availability whichever comes first. The dose in part 2 may be adjusted as per additional safety and Bayesian popPK analyses. |
| Part 1 and 2: Cohort C1 | EXPERIMENTAL | Cohort C1 will contain participants 2 to \<7 years of age. Participants will receive a single oral dose of omaveloxolone, capsule, at a dosage level determined by a Bayesian popPK analysis using the data from cohorts A1, A2, and B1 to select the dose in part 1, followed by the same dose in part 2 up to week 240 or commercial availability whichever comes first. The dose in part 2 may be adjusted as per additional safety and Bayesian popPK analyses. |
| Part 1 and 2: Cohort A3 | EXPERIMENTAL | Cohort A3 will contain participants 12 to \<16 years of age. Participants will receive a single oral dose of omaveloxolone, capsule, at a dosage level determined by a Bayesian popPK analysis using the data from cohorts A1, A2, and B1 to select the dose in part 1, followed by the same dose in part 2 up to week 240 or commercial availability whichever comes first. The dose in part 2 may be adjusted as per additional safety and Bayesian popPK analyses. |
| Part 1 and 2: Cohort B2 | EXPERIMENTAL | Cohort B2 will contain participants 7 to \<12 years of age and will initiate in parallel with Cohort A3. Participants will receive a single oral dose of omaveloxolone, capsule, at a dosage level determined by a Bayesian popPK analysis using the data from cohorts A1, A2, and B1 to select the dose in part 1, followed by the same dose in part 2 up to week 240 or commercial availability whichever comes first. The dose in part 2 may be adjusted as per additional safety and Bayesian popPK analyses. |
| Part 1 and 2: Cohort C2 | EXPERIMENTAL | Cohort C2 will contain participants 2 to \<7 years of age. Participants will receive a single oral dose of omaveloxolone, capsule, at a dosage level determined by a Bayesian popPK analysis using the data from Cohorts A1, A2, A3, B1, B2, and C1 to select the dose in part 1, followed by the same dose in part 2 up to week 240 or commercial availability whichever comes first. The dose in part 2 may be adjusted as per additional safety and Bayesian popPK analyses. |
| Name | Type | Description |
|---|---|---|
| Omaveloxolone | DRUG | Administered as specified in the treatment arm. |
| Placebo | DRUG | Administered as specified in the treatment arm. |
| Omaveloxolone Capsules, 2.5 mg | DRUG | - |
| Omaveloxolone Capsules, 5 mg | DRUG | - |
| Omaveloxolone Capsules, 10 mg | DRUG | - |
| Omaveloxolone Capsules, 20 mg | DRUG | - |
| Omaveloxolone Capsules, 40 mg | DRUG | - |
| Omaveloxolone Capsules, 80 mg | DRUG | - |
| Omaveloxolone Capsules, 160 mg | DRUG | - |
| Omaveloxolone Capsules, 300 mg | DRUG | - |
| Omaveloxolone Capsules, 150 mg | DRUG | - |
Part 1: Key inclusion criteria: * Diagnosed with genetically confirmed Friedreich's Ataxia (FA), i.e., homozygous for guanine-adenine-adenine (GAA) repeat expansion in intron-1 of the frataxin gene, or GAA repeat expansion in 1 allele and with point mutations or deletions, or other non-GAA expansio...